2024
Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia
Hunter C, Bewersdorf J, Mendez L, Podoltsev N, Zeidan A, Eighmy W, Roeder H, Malinis M, Shallis R. Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia. Blood 2024, 144: 1480-1480. DOI: 10.1182/blood-2024-211250.Peer-Reviewed Original ResearchInvasive fungal infectionsAcute myeloid leukemiaAntifungal prophylaxisDiagnosed AMLDrug-drug interactionsTransaminase elevationVisual disturbancesRates of invasive fungal infectionsInvasive fungal infections incidenceBaseline ANCCD4 countMyeloid leukemiaAllogeneic stem cell transplantationAnti-fungal prophylaxisAcute myeloid leukemia diagnosisDuration of neutropeniaBaseline CD4 countLess-intensive therapyStem cell transplantationPatient baseline characteristicsSide effect profileCandida sppTriazole agentsWilcoxon rank sum testAntifungal voriconazole
2021
Management of the Older Patient with Myelodysplastic Syndrome
Shallis RM, Zeidan AM. Management of the Older Patient with Myelodysplastic Syndrome. Drugs & Aging 2021, 38: 751-767. PMID: 34342860, DOI: 10.1007/s40266-021-00881-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeOlder patientsAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationPrevalence of frailtyMajority of patientsStem cell transplantationPatient-specific factorsDrug-drug interactionsQuality of lifeAbsolute contraindicationPalliative therapyCare therapyCurative therapyIntensive therapyCell transplantationOptimal treatmentSubgroup analysisPatientsPsychosocial issuesSyndromeTherapyPersonalized treatmentAge associatesOlder population